Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Myriad Genetics (MYGN) over the last 12 years, with Q3 2025 value amounting to $7.5 million.

  • Myriad Genetics' Treasury Shares rose 4423.08% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 4423.08%. This contributed to the annual value of $5.3 million for FY2024, which is 2045.45% up from last year.
  • Per Myriad Genetics' latest filing, its Treasury Shares stood at $7.5 million for Q3 2025, which was up 4423.08% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Treasury Shares registered a high of $7.6 million during Q2 2025, and its lowest value of $3.1 million during Q4 2021.
  • In the last 5 years, Myriad Genetics' Treasury Shares had a median value of $4.6 million in 2023 and averaged $4.8 million.
  • In the last 5 years, Myriad Genetics' Treasury Shares skyrocketed by 7894.74% in 2021 and then tumbled by 892.86% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Treasury Shares stood at $3.1 million in 2021, then rose by 19.35% to $3.7 million in 2022, then grew by 18.92% to $4.4 million in 2023, then rose by 20.45% to $5.3 million in 2024, then skyrocketed by 41.51% to $7.5 million in 2025.
  • Its Treasury Shares was $7.5 million in Q3 2025, compared to $7.6 million in Q2 2025 and $5.1 million in Q1 2025.